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Abstract: Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only 
therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food 
and Drug Administration (US FDA) approvals of sipuleucel-T, cabazitaxel, and abiraterone acetate, all based on improvement in overall 
survival, the landscape for management of men with metastatic CRPC has dramatically changed. In this review we will discuss the 
pivotal clinical trial data leading to these approvals, with particular focus on the unique indication for sipuleucel-T and the implications 
for optimal management and sequencing of treatment in this patient population.
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Introduction
Prostate cancer is the most common non-skin malig-
nancy and the second leading cause of cancer death in 
men in the United States.1 Surgery and radiation are 
effective  therapies  for  localized  prostate  cancer,  but 
prostate cancer will recur in 20%–40% of these patients 
after  local  therapy.2  Androgen  deprivation  therapy 
(ADT) stabilizes the disease in most patients,   however, 
over  time  patients  will  develop  castration-resistant 
prostate cancer (CRPC). Until recently, available thera-
peutic options for these patients have been limited to 
off-label use of secondary hormonal manipulations or 
docetaxel  with  prednisone,  which  demonstrated  the 
only  improvement  in  median  survival  for  this 
population.3,4 The landscape changed dramatically in 
2010 with the U.S. FDA approval of the autologous cel-
lular  immunotherapy  sipuleucel-T  (PROVENGE®; 
Dendreon Corp. Seattle, WA, USA) for the treatment of 
men  with  asymptomatic  or  minimally  symptomatic 
metastatic  CRPC.5  Shortly  thereafter,  cabazitaxel/ 
prednisone was approved by the FDA for the treatment 
of men with metastatic CRPC previously treated with 
docetaxel  chemotherapy.6  Both  sipuleucel-T  and 
  cabazitaxel/prednisone were shown to further   extend 
median  overall  survival.  Most  recently,  abiraterone 
  acetate/prednisone, an oral CYP17 inhibitor of adrenal 
steroid synthesis, has also been shown to improve sur-
vival in patients who progress on taxane-based chemo-
therapy  and  is  now  U.S.  FDA  approved  in  the 
post-docetaxel setting for men with CRPC.7 The rela-
tively sudden increase in treatment options for men 
with metastatic CRPC is a benefit for patients but leaves 
open to   interpretation for practitioners the best strategy 
and sequence of  therapies in this disease setting. With this 
in mind, we have reviewed the data regarding these 
therapeutic options with particular focus on the emerg-
ing strategies for incorporating sipuleucel-T into this 
changing landscape.
systemic Therapy in Metastatic cRpc
Historically, the role of chemotherapy in metastatic 
prostate  cancer  was  limited  to  symptom  palliation 
with  the  use  of  mitoxantrone  and  prednisone.8,9 
In 2004, the TAX327 study showed that treatment 
with docetaxel and prednisone prolonged overall sur-
vival compared to mitoxantrone and prednisone in 
metastatic CRPC patients.4 Patients treated with doc-
etaxel and prednisone also had improved palliation of 
disease-related  symptoms,  compared  to  those 
  receiving treatment with prednisone alone. Similarly, 
the SWOG9916 trial showed a significant overall and 
progression-free survival benefit in patients receiving 
docetaxel  and  estramustine  versus  those  receiving 
mitoxantrone and prednisone, with the relative risk 
for death 20% lower in patients receiving docetaxel-
based therapy (hazard ratio (HR) 0.80; 95% confi-
dence interval (CI) 0.67–0.97).3
Docetaxel/prednisone was the only approved che-
motherapeutic regimen that improved median survival 
in men with metastatic CRPC until data was reported 
on the novel taxane, cabazitaxel, in 2010.The TROPIC 
study was a randomized, phase 3 study of 755 men 
which examined the effect on survival of cabazitaxel 
plus prednisone versus mitoxantrone plus prednisone 
in patients who had progressed on   docetaxel-based 
chemotherapy. Treatment with   cabazitaxel/prednisone 
resulted in an improvement in median overall survival 
by  2.8  months  with  a  30%  reduced  risk  of  death 
(HR 0.7, 95% CI 0.59–0.83).6 This led to U.S. FDA 
approval of cabazitaxel plus prednisone for patients 
with metastatic CRPC previously treated with doc-
etaxel and prednisone.
At  the  European  Society  for  Medical  Oncology 
meeting in late 2010, survival data from a pre-planned 
interim analysis of the international phase 3 Cougar 
301 study of abiraterone acetate and prednisone versus 
placebo and prednisone was presented. Nearly 1200 
patients  with  metastatic  CRPC  progressing  after 
  docetaxel-based chemotherapy were randomized 2:1 
to receive abiraterone acetate and prednisone or pla-
cebo and prednisone; the primary endpoint was overall 
survival. Treatment with abiraterone/prednisone led to 
a 35% reduction in the risk of death (HR 0.65, 95% 
CI  0.54–0.77),  with  an  improvement  in  survival  of 
3.9  months  over  placebo/prednisone.7  Updated  sur-
vival  data  after  median  follow-up  of  20.2  months 
showed  an  even  greater  survival  benefit  in  the 
  abiraterone/prednisone arm of 4.6 months over   placebo/
prednisone  (HR  0.74,  P  ,  0.001).10    Furthermore, 
improvement in the abiraterone/prednisone arm was 
also  seen  in  time  to  progression,  radiographic 
  progression-free survival, and prostate-specific antigen 
(PSA)  response,7  leading  to  the  April  2011  U.S. 
  FDA-approval of abiraterone acetate and prednisone in 
the post-  docetaxel setting. An ongoing phase 3 trial of 
abiraterone acetate with prednisone in the   pre-  docetaxel Management options in advanced prostate cancer
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setting is evaluating the earlier use of this active agent 
in men with metastatic CRPC.
The recent approvals of sipuleucel-T, cabazitaxel/
prednisone, and abiraterone/prednisone for the treat-
ment of patients with metastatic prostate cancer have 
significantly  changed  the  disease  landscape.  The 
newly approved agents for the treatment of advanced 
prostate cancer are summarized in Table 1. How best 
to  incorporate  immunotherapy,  chemotherapy,  and 
further hormonal therapy into the treatment paradigm 
of patients with metastatic CRPC remains unclear, 
especially given that prednisone is a component of 
therapy with abiraterone, docetaxel, and cabazitaxel 
but is not recommended during sipuleucel-T therapy 
due  to  its  immunosuppressive  properties.  While 
  docetaxel-based therapy has an established treatment 
paradigm and cabazitaxel and abiraterone were both 
reported in studies following docetaxel-based chemo-
therapy,  the  incorporation  of  sipuleucel-T  in  some 
respects represents the greatest challenge, based on 
its novel mechanism of action, limited response pro-
file, unique FDA label, access, and cost. We discuss 
these issues and how they may shape the current and 
future use of this new treatment.
sipuleucel-T
Sipuleucel-T is a therapeutic vaccine in which autolo-
gous antigen-presenting cells are activated by expo-
sure to a recombinant antigen called PA2024. PA2024 
is a chimeric protein containing the tumor-associated 
antigen  prostatic  acid  phosphatase  together  with 
  granulocyte-macrophage colony-stimulating factor to 
activate the immune cells. Therapy with sipuleucel-T 
involves leukapheresis, during which peripheral blood 
mononuclear cells containing antigen-  presenting cells 
are collected and cultured ex vivo at a designed   facility 
for approximately 36 hours with the PA2024 antigen. 
The cell product is then delivered to the treatment site, 
and the primed cells are infused into the same patient 
from which they were collected. Each round of ther-
apy consists of leukapheresis followed by intravenous 
infusion of the primed antigen-presenting cells, and 
treatment is given every two weeks for a total of three 
treatments. The mechanism of action, therefore, is to 
engage the patient’s immune response to attack the 
prostate cancer cells specifically.
Two randomized, multicenter, double-blind phase III 
trials compared sipuleucel-T with placebo in men with 
metastatic  CRPC.  The  first  trial,  known  as  D9901, 
enrolled 127 patients and failed to meet its primary 
endpoint of progression-free survival (PFS), with time 
to progression of 11.7 weeks for the   sipuleucel-T arm 
and 10 weeks for the placebo arm (P = 0.52).11 As a 
result, the second trial (D9902) was closed after only 
98 patients enrolled.12 However, when the overall sur-
vival data for D9901 became available and showed a 
statistically-significant  4-month  improvement  in  the 
sipuleucel-T arm, the second trial was split into two 
parts: D9902 A, which included the 98 patients already 
enrolled,  and  D9902B,  which  was  revised  to  make 
overall survival the primary endpoint.
D9902B became known as the IMPACT (Immu-
notherapy for Prostate Adeno Carcinoma Treatment) 
trial and enrolled 512 men with metastatic CRPC with 
a life expectancy of at least 6 months.5 Initially only 
men  with  asymptomatic  disease  and  a  Gleason 
score # 7 were enrolled; however, once the survival 
benefit from D9901 was shown to be independent of 
histologic grade, the study was amended to include 
asymptomatic  or  minimally  symptomatic  patients 
Table 1. newly approved agents in CRPC. 
Agent Mechanism of action Indication PFS benefit OS benefit
Sipuleucel-T  
(PROvenGe®)
Autologous cellular  
immunotherapy  
(PAP-directed)
Asymptomatic to  
minimally symtomatic  
metastatic CRPC
none 4.1 months vs. placebo  
(HR 0.78, 95% CI 0.61–0.98)5
Cabazitaxel  
(Jevtana®)
Microtubule  
inhibition
Metastatic CRPC,  
post-docetaxel
1.4 months 2.8 months vs. mitoxantrone  
(HR 0.70, 95% CI 0.59–0.83)6
Abiraterone  
(Zytiga®)
CYP17a inhibitor of  
adrenal and autocrine/ 
paracrine androgen  
biosynthesis
Metastatic CPRC,  
post-docetaxel
2.0 months 4.6 months vs. prednisone  
(HR 0.74, 95% CI  
0.64–0.86)10
Abbreviation: PAP, Prostatic Acid Phosphatase.Bitting et al
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with any Gleason score. Additionally, patients were 
required to have a PSA level of $5 ng/mL,   testosterone 
of #50 ng/dL, and evidence of progressive disease. 
Patients with an ECOG performance status of $2, 
visceral metastases, pathologic long-bone fractures, 
or those receiving two or more prior chemotherapy 
regimens  were  excluded.  Patients  were  randomly 
assigned in a 2:1 ratio to receive either sipuleucel-T 
or placebo, in which the autologous cells were not 
exposed to the chimeric protein. The primary   endpoint 
was overall survival, with time to disease progression 
as the secondary endpoint.
The  IMPACT  study  conclusively  confirmed  the 
overall survival advantage previously seen for patients 
receiving  sipuleucel-T  vs.  placebo.  Patients  in  the 
sipuleucel-T-treatment arm had a 22% reduction in 
risk of death (HR 0.78, 95% CI 0.61–0.98; P = 0.032) 
and  a  4.1-month  improvement  in  median  survival 
(25.8  vs.  21.7  months),  as  illustrated  in  Figure  1. 
The  36-month  survival  probability  was  32.1%  for 
sipuleucel-T versus 23% for control. Similar to the 
prior studies, no difference in PFS was noted between 
the  two  arms,  with  progression  documented  at 
14.6 weeks in the sipuleucel-T arm and at 14.4 weeks 
in the placebo arm. Likewise, there was no significant 
difference in PSA response or decrease in tumor size 
by imaging, and given that men were asymptomatic 
to minimally symptomatic, no palliative benefit or 
delay in pain onset or time to chemotherapy was noted 
with sipuleucel-T.5 The fact that a PFS advantage was 
not seen in the context of this novel immune therapy 
is  consistent  with  other  immunotherapies,  such  as 
ipilimumab  in  melanoma.13  Recent  guidelines  for 
interpreting the benefits of immunotherapies in can-
cer have been published, which may better account 
for delayed onset treatment effects that are not well 
captured using current methods.14
Integrated safety results from more than 600 patients 
from four randomized, double-blind sipuleucel-T stud-
ies,  three  studies  in  CRPC  and  one  in  androgen- 
dependent  prostate  cancer,  showed  that  the  most 
common side-effects associated with sipuleucel-T were 
chills, pyrexia, headache, and myalgia. Most of the 
reactions occurred the day after infusion, were mild or 
moderate in severity, and resolved within 2 days. Side 
effects were slightly more common after the second 
and third infusions than the first infusion.15
More than half of patients in the placebo group of 
the IMPACT study (109 of 171 patients) crossed over 
to receive APC8015F as part of an open-label salvage 
protocol. APC8015F is made from the cryo preserved 
leukophoresis product and is otherwise manufactured 
and administered identically to sipuleucel-T. A recent 
combined analysis of the patients in the control arms 
of the three randomized trials of sipuleucel-T in meta-
static CRPC aimed to assess the efficacy of treatment 
with APC8015F. APC8015F-treated subjects (n = 155) 
had improved survival relative to untreated controls 
(n = 61), with a 48% reduced risk of death (HR = 0.52, 
95%  CI  0.37–0.73). When  adjusted  for  age,  PSA, 
LDH,  and  docetaxel  treatment  after  randomization 
the significant survival benefit remained (HR 0.56, 
95% CI 0.4–0.8).16 Although confounded by unmea-
sured factors related to the non-random use of the fro-
zen product, this analysis suggests that treatment with 
APC8015F was not associated with a worse outcome 
and may prolong overall survival. If so, the survival 
benefit noted in the sipuleucel-T versus placebo arms 
of the trials may actually be an underestimate com-
pared to a true no-treatment control.
The implications of treatment with sipuleucel-T on 
current practice are significant. Sipuleucel-T is FDA-
approved for asymptomatic or minimally symptom-
atic men with metastatic disease, which consequently 
requires more aggressive screening of men with CRPC 
for evidence of metastatic disease.   Historically, many 
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Figure 1. Overall survival benefit of 4.1 months (P = 0.03) with   sipuleucel-T 
treatment. 
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patients in the asymptomatic CRPC disease state have 
been managed conservatively with continued ADT, 
secondary hormonal manipulations, or expectant man-
agement. Active screening of men with asymptomatic 
non-metastatic CRPC for the development of metasta-
ses  is  therefore  increasingly  important  to  identify 
patients for treatment with sipuleucel-T as well as for 
bone-targeted therapy.
Asymptomatic and Minimally 
symptomatic Metastatic cRpc
The approval of sipuleucel-T for patients with asymp-
tomatic  metastatic  disease  should  result  in  more 
aggressive screening for the development of metasta-
ses. Currently, most patients with biochemical relapse 
after  definitive  therapy  are  treated  with  androgen 
deprivation therapy. The majority of these patients 
will have a PSA response, though eventually the PSA 
will  rise  again.  There  is  no  standard  surveillance 
method or treatment for patients with a rising PSA 
despite ADT, and a previous observational study of 
more than 200 men showed that many of these patients 
have no evidence of metastatic disease until a median 
of 30 months.17 However, a recent study designed to 
treat non-metastatic CRPC patients with zibotentan 
versus placebo revealed an unexpectedly high num-
ber screening failures, prompting further analysis. Of 
the more than 1,700 patients screened for metastases 
by bone scan and CT or MRI, 531 patients (30%) 
failed screening due to the presence of metastatic dis-
ease.18 This suggests that asymptomatic metastases 
are common and supports the role of periodic staging 
studies  in  men  with  CRPC,  particularly  given  the 
expanded treatment options for these men.
Poor risk prognostic factors have been identified to 
help providers predict metastatic disease progression 
and  survival  in  men  with  non-metastatic  CRPC. As 
mentioned above, an observational study of more than 
200 men with non-metastatic CRPC revealed a rela-
tively indolent course with median time to metastasis of 
30 months. However, in that study, both the PSA and 
the PSA doubling time (PSA DT) were directly propor-
tional to the time to metastases.   Specifically, patients 
with a PSA level . 24 ng/ml or a PSA DT , 6.3 months 
developed  metastases  or  death  at  a  median  of 
,12  months.  Even  those  patients  with  PSA  levels 
. 7.7 ng/ml or PSA DT , 18.8 months had a 25%–30% 
likelihood of developing metastases or death within one 
year.14 These data suggest that patients who are started 
on primary ADT without metastases should be radio-
graphically restaged regularly (perhaps every 4 months 
as in the study above) for evidence of metastatic disease 
once they become castration-  resistant, if they have a 
PSA DT , 18 months or a PSA level . 7.7 ng/ml.
Among men with metastatic CRPC, this asymp-
tomatic to minimally symptomatic population has a 
favorable survival. In the TAX327 study, a good risk 
population was identified that lacked pain, visceral 
metastatic  disease,  significant  anemia,  and  bone 
scan progression, despite having progressive meta-
static CRPC. These men had an expected survival 
of 23–28 months, and a one year survival rate of 
80%–90%.19 Thus, the use of less toxic therapies 
such as immunotherapy in this setting, where pro-
longed survival rather than palliation of symptoms is 
the primary goal, is quite reasonable.
Regular surveillance for metastatic disease is also 
crucial for the proper use of bone-targeting therapies 
such as zoledronic acid or denosumab. The bisphos-
phonate zoledronic acid is superior to placebo in pre-
venting skeletal-related events (SRE) and prolonging 
the time to the first SRE, and has been a mainstay of 
supportive  therapy  for  patients  with  metastatic 
CRPC.20  Denosumab  is  a  humanized  monoclonal 
antibody that binds to RANKL, a protein important 
for  osteoclast  function.  Zoledronic  acid  and  deno-
sumab were compared in a phase 3 study of men with 
metastatic CRPC, and both agents were effective in 
preventing SREs, defined as pathologic fracture, radi-
ation therapy to bone, surgery to bone, or spinal cord 
compression.  Compared  to  zoledronic  acid,  men 
receiving denosumab had improved time to first SRE 
(20.7 vs. 17.1 months, P = 0.008), but there was no 
difference in progression-free or overall survival.21 
On the basis of this and two other large non-inferior-
ity studies, denosumab is U.S. FDA-approved for the 
prevention of SREs in metastatic prostate and other 
solid tumors. Therefore, early identification of patients 
with metastatic disease provides the opportunity to 
offer bone-targeting therapy to prevent SREs as well 
as immunotherapy to prolong survival.
sequencing of Therapy
With the recent approval of multiple new agents for 
metastatic prostate cancer comes the question of how 
best to sequence therapy. In the IMPACT study, the Bitting et al
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majority  of  patients  received  sipuleucel-T  prior  to 
treatment with docetaxel/prednisone. In contrast, in 
the  TROPIC  study,  patients  received  cabazitaxel/
prednisone  following  progression  on  docetaxel/ 
prednisone,  and  a  statistically  significant  survival 
benefit was demonstrated. Similarly, in Cougar 301, 
patients  received  abiraterone/prednisone  following 
progression on docetaxel/prednisone and again dem-
onstrated a statistically significant survival benefit.
There  is  great  interest  in  using  abiraterone/ 
prednisone earlier in the course of disease, as it is an 
oral regimen that has been well-tolerated. Cougar 302 
is currently accruing and is designed to look at giving 
abiraterone/prednisone early, to the minimally symp-
tomatic  metastatic  patient,  potentially  followed  by 
treatment with sipuleucel-T, docetaxel/prednisone, and 
cabazitaxel/prednisone. However, the current phase III 
evidence suggests that sipuleucel-T should be given 
early  to  asymptomatic  or  minimally  symptomatic 
CRPC patients, followed by docetaxel/  prednisone, fol-
lowed  then  by  either  abiraterone/prednisone  or 
  cabazitaxel/prednisone.  Ongoing  studies  will  likely 
further alter the recommended strategy for treatment 
sequencing. Importantly, not all CRPC patients will 
qualify for sipuleucel-T based on their symptoms or 
histologic type of prostate cancer, so no single sequence 
of treatments will be optimal for all patients.
In the IMPACT study, approximately eighty-five 
percent  of  patients  treated  with  sipuleucel-T  were 
chemotherapy-naïve.5 Due to the time it takes for the 
patient’s  anti-tumor  response  to  fully  develop,  the 
absolute benefit associated with sipuleucel-T therapy 
may increase with longer survival; therefore, admin-
istering immunotherapy early in CRPC may maxi-
mize  the  efficacy  and  cost-effectiveness  of  this 
treatment. An ongoing phase III study of sipuleucel-T 
versus placebo in hormone-sensitive, non-metastatic 
prostate cancer patients will help to address this issue. 
Also, because the chemotherapeutic agents and abi-
raterone are administered with concomitant steroid 
therapy,  there  is  likely  benefit  to  treatment  with 
sipuleucel-T prior to initiation of immunosuppressive 
medications. To date it is unclear how long it is neces-
sary to wait before starting another treatment follow-
ing sipuleucel-T; however, there is theoretical concern 
that immediate subsequent treatment with immuno-
suppressive agents could impact the mechanism of 
action of sipuleucel-T.
Low-dose corticosteroids are an integral part of 
the systemic therapy for metastatic prostate cancer. 
In  part,  this  is  historical,  as  the  anti-inflammatory 
properties of steroids are known to improve pain and 
palliate disease symptoms.22 An early trial of cyto-
toxic therapy in metastatic CRPC compared mitoxan-
trone plus prednisone to prednisone alone and found 
improved palliation with the combined therapy.8 Most 
subsequent trials have used mitoxantrone plus pred-
nisone as the control arm; therefore, both docetaxel 
and cabazitaxel are administered with daily low-dose 
corticosteroids.  Low-dose  prednisone  is  also  used 
with the CYP17 inhibitor abiraterone, based on the 
drug’s  effects  on  the  adrenal  corticosteroid  axis. 
CYP17 inhibition raises levels of adrenal corticotro-
pic hormone (ACTH), and without exogenous gluco-
corticoid administration, may cause a syndrome of 
mineralocorticoid  excess  including  hypertension, 
fluid retention, and hypokalemia.23 As a result of mul-
tiple agents being administered with corticosteroids, 
patients with metastatic CRPC may now remain on 
low-dose steroid therapy for months to years. Chronic 
steroid therapy is associated with well-documented 
side  effects  including  hypertension,  steroid  depen-
dence,  peptic  ulcer  disease,  weight  gain,  glucose 
intolerance, glaucoma, and risk of infection. There-
fore, what was initially intended to be a palliative 
measure is now given with several different therapies 
and may have unintended consequences.
Corticosteroids also attenuate the immune response 
and therefore are not recommended to be given with 
sipuleucel-T. In the IMPACT study, steroids were not 
given within 28 days of sipuleucel-T initiation and 
were not resumed until there was objective evidence 
of disease progression. The median time to progres-
sion was 14 weeks, and given that the therapy itself 
requires 4 weeks to administer, most patients therefore 
received subsequent treatment within a few months of 
completion  of  sipuleucel-T.  Two  thirds  of  patients 
receiving  sipuleucel-T  had  a  measurable  antibody 
response to the immunogen and survival was improved 
in these patients.5 It is unclear what effect, if any, sub-
sequent low-dose steroid therapy has on the long-term 
efficacy of sipuleucel-T and other immunotherapies. 
There is preclinical evidence that that glucocorticoids 
may  not  interfere  with  the  antitumor  response  of 
immunotherapy,24 but this needs to be further studied 
in prostate cancer patients. No controlled studies of Management options in advanced prostate cancer
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differential timing of subsequent therapies have been 
conducted, and treatment decisions after sipuleucel-T 
are typically made by clinical judgment over the risks 
and benefits of withholding or starting a new systemic 
agent. The use of prior sipuleucel-T is one of many 
factors, including also the rapidity of disease progres-
sion,  tumor-related  symptoms,  and  patient  anxiety, 
which should be considered when deciding on subse-
quent systemic agents.
Access to sipuleucel-T
On-label treatment with sipuleucel-T is currently cov-
ered  by  Medicare  and  most  other  large  insurance 
companies; in fact, the Centers of Medicare and Med-
icaid Services (CMS) released a national coverage 
decision stating that sipuleucel treatment is ‘reason-
able and necessary’.25 However, to this point in time, 
access  to  sipuleucel-T  has  been  limited  by  the 
restricted number of treatment centers, the production 
capability of the manufacturing plant, and the logisti-
cal limitations of flying the product to areas of the 
country remotely accessed from the manufacturing 
facility in New Jersey. The addition of manufacturing 
facilities in Atlanta and Southern California later this 
year will alleviate this concern for many, but not all, 
rural patients. Finally, there remain clinicians who are 
not convinced of the effectiveness of this therapy, 
either because of its novel but not yet fully established 
mechanism of action, or its lack of intermediate end-
point benefit (PFS or PSA response), and therefore 
are unwilling to treat patients with this life-prolong-
ing therapy.
conclusion
Treatment with sipuleucel-T therapy improves over-
all survival without a measurable immediate antitu-
mor  effect.  The  therapy  should  be  given  to 
asymptomatic or minimally symptomatic men with 
metastatic CRPC, and as such, patients need to be 
restaged regularly to optimally identify this popula-
tion. Phase III evidence supports the early use of 
sipuleucel-T therapy prior to docetaxel/prednisone 
therapy in most cases. Availability, cost of therapy, 
physician bias as well as established and emerging 
alternative treatments remain barriers to care with 
sipuleucel-T.  Future  data  establishing  subpopula-
tions of patients with greater benefit from   sipuleucel-T 
as  well  as  adjuvant  immune  modulation  of  this 
  platform  are  needed  to  build  upon  the  promising 
results of today.
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